Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploration of Plasma CDO1 and HOXA9 DNA Methylation for Detecting Epithelial Ovarian Cancer: A Clinical Trial in China

NCT05801276 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT05801276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05801276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploration of Plasma CDO1 and HOXA9 DNA Methylation for Detecting Epithelial Ovarian Cancer: A Clinical Trial in China
Lead sponsor
Lei Li
Phase
Observational
Overall status
Unknown status
Start date
March 24, 2023
Completion date
March 24, 2026
Enrollment
1,400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ca125, circulating tumor dna, dna methylation, epithelial ovarian cancer, human epididymis protein 4, imaging evaluation, non-invasive diagnosis, roma index, survival prognosis